Education
About Us
Working with TipRanks
Follow Us
Cabaletta Bio (CABA)
NASDAQ:CABA
CABA Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CABA Stock 12 Month Forecast
Average Price Target
$27.50
▲(1480.46% Upside)
| Highest Price Target$30.00 | Average Price Target$27.50 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
02/18/25
William Blair
Reiterated
02/18/25
Morgan Stanley
Reiterated
02/18/25
Evercore ISI
$6
Hold
244.83%
Upside
Downgraded
12/20/24
Cabaletta Bio downgraded to In Line from Outperform at Evercore ISICabaletta Bio downgraded to In Line from Outperform at Evercore ISI
Wells Fargo
$12→$6
Hold
244.83%
Upside
Downgraded
12/19/24
Analysts Conflicted on These Healthcare Names: Verastem (NASDAQ: VSTM), Roche Holding AG (Other OTC: RHHVF) and Cabaletta Bio (NASDAQ: CABA)
Guggenheim
$23
Buy
1221.84%
Upside
Reiterated
11/14/24
Guggenheim reiterates Buy Rating on Cabaletta Bio Inc. (CABA)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $23.00 price target on Cabaletta Bio Inc. (NASDAQ: CABA).
TD Cowen
―
Buy
―
Reiterated
11/14/24
Cabaletta Bio's Promising Trial Results and Proactive Management Secure Buy Rating
Citi
$17
Buy
877.01%
Upside
Reiterated
11/14/24
Strong Momentum and Promising Data Drive Buy Opportunity for Cabaletta Bio's CABA-201
Stifel Nicolaus
$26
Buy
1394.25%
Upside
Reiterated
11/05/24
Stifel Nicolaus Reaffirms Their Buy Rating on Cabaletta Bio (CABA)
UBS
$10
Buy
474.71%
Upside
Initiated
10/10/24
Cabaletta Bio initiated with a Buy at UBSCabaletta Bio initiated with a Buy at UBS
Cantor Fitzgerald
$50
Buy
2773.56%
Upside
Reiterated
06/20/24
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Cabaletta Bio (NASDAQ: CABA)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
02/18/25
William Blair
Reiterated
02/18/25
Morgan Stanley
Reiterated
02/18/25
Evercore ISI
$6
Hold
244.83%
Upside
Downgraded
12/20/24
Cabaletta Bio downgraded to In Line from Outperform at Evercore ISICabaletta Bio downgraded to In Line from Outperform at Evercore ISI
Wells Fargo
$12→$6
Hold
244.83%
Upside
Downgraded
12/19/24
Analysts Conflicted on These Healthcare Names: Verastem (NASDAQ: VSTM), Roche Holding AG (Other OTC: RHHVF) and Cabaletta Bio (NASDAQ: CABA)
Guggenheim
$23
Buy
1221.84%
Upside
Reiterated
11/14/24
Guggenheim reiterates Buy Rating on Cabaletta Bio Inc. (CABA)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $23.00 price target on Cabaletta Bio Inc. (NASDAQ: CABA).
TD Cowen
―
Buy
―
Reiterated
11/14/24
Cabaletta Bio's Promising Trial Results and Proactive Management Secure Buy Rating
Citi
$17
Buy
877.01%
Upside
Reiterated
11/14/24
Strong Momentum and Promising Data Drive Buy Opportunity for Cabaletta Bio's CABA-201
Stifel Nicolaus
$26
Buy
1394.25%
Upside
Reiterated
11/05/24
Stifel Nicolaus Reaffirms Their Buy Rating on Cabaletta Bio (CABA)
UBS
$10
Buy
474.71%
Upside
Initiated
10/10/24
Cabaletta Bio initiated with a Buy at UBSCabaletta Bio initiated with a Buy at UBS
Cantor Fitzgerald
$50
Buy
2773.56%
Upside
Reiterated
06/20/24
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Cabaletta Bio (NASDAQ: CABA)
Best Analysts Covering Cabaletta Bio
Which Analyst Should I Follow If I Want to Buy CABA and Sell After:
1 Month
xxx
Success Rate
9/21 ratings generated profit
Average Return
+9.69%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +9.69% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
+82.43%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +82.43% per trade.
1 Year
Success Rate
10/21 ratings generated profit
Average Return
+173.71%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +173.71% per trade.
2 Years
xxx
Success Rate
6/21 ratings generated profit
Average Return
+70.92%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of +70.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CABA Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
12
11
8
8
3
Buy
2
3
3
4
2
Hold
0
0
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
14
13
14
7
Each month's total comprises the sum of three months' worth of ratings.
CABA Financial Forecast
CABA Stock Forecast FAQ
What is CABA’s average 12-month price target, according to analysts?
Based on analyst ratings, Cabaletta Bio’s 12-month average price target is $27.50.
What is CABA’s upside potential, based on the analysts’ average price target?
Cabaletta Bio has 1480.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CABA a Buy, Sell or Hold?
Cabaletta Bio has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Cabaletta Bio’s price target?
The average price target for Cabaletta Bio is $27.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $25.00. The average price target represents 1480.46% Increase from the current price of $1.74.
The highest analyst price target is $30.00 ,the lowest forecast is $25.00. The average price target represents 1480.46% Increase from the current price of $1.74.
What do analysts say about Cabaletta Bio?
Cabaletta Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of CABA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.